Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S. Korea Report Accuses Generics Makers Of Overpricing

This article was originally published in PharmAsia News

Executive Summary

South Korea's drug authority accused the country's drug makers of inflating the prices of their generic drugs. The Korea Development Institute said in a report that some drug makers sell generics for prices close to the price of the brand-name drug even though the generic makers experienced no development costs. In some cases, it said, the generic price is as close as 80 percent of the brand price. A KDI researcher attributed some of the pricing to government controls that set prices based on hospital negotiations with drug makers who give kickbacks to the hospitals. The reported noted that 80 percent of drugs sold in South Korea are generics. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel